Advances in Cancer Immunotherapyâ„¢- Chicago, Illinois

Cancer Immunotherapy 101 Thursday, June 23, 2016 • 4:00 – 8:00 p.m. Hyatt Regency McCormick Place Organizers Linda A. Janisch, APN – University of Chicago Timothy M. Kuzel, MD – Rush University Medical Center Jason J. Luke, MD, FACP – University of Chicago

Program Purpose

Specifically designed for clinical oncologists, registered nurses, pharmacists and the entire medical team involved in treating cancer patients with immunotherapy, this introductory, CME- and CE-certified program provided an overview of basic immunology principles and the mechanisms and clinical applications of immunotherapy for melanoma, lung cancer and genitourinary cancers.

Presented by leading authorities in tumor immunology and cancer immunotherapy, this program facilitated understanding of 1) the basic principles of tumor immunology and immunotherapy, 2) the clinical indications for immunotherapy and the appropriate selection and management of patients, 3) emerging concepts and agents in the cancer immunotherapy field, and 4) the therapeutic effectiveness of immunotherapy to ultimately improve patient outcomes. 

Attendees also took advantage of the opportunity for professional networking that will promote collaboration and scientific exchange with experts, clinical oncologists and other health care providers from the surrounding community.

Intended Audience

The target audience for this program was patient care providers and others who wished to learn the basic principles of tumor immunology and immunotherapy, and improve their ability to integrate immunotherapy into state-of-the art clinical management for their patients. This intended audience included clinical oncologists, registered nurses, nurse practitioners, pharmacists, allied health professionals, other patient care providers, students and patient advocates.

Session Topics

• Immunology and Immunotherapy 101 for the Non-Immunologist
• Basic Principles of Tumor Immunotherapy
• Immunotherapy for the Treatment of:
  • Lung Cancer
  • Melanoma
  • Genitourinary Cancers
• Immunotherapy on the Horizon

Pre-Program Materials

Attendees benefited from reviewing the pre-program material located here. These slides provided an overview of immunology principles that were also covered during the program and introduced participants to the immunological mechanisms underlying immunotherapy approaches. The program on June 23 began by offering attendees the opportunity to ask questions about these slides, followed by a presentation about this information, especially as it pertains to immunotherapy.

Educational Objectives

Upon completion of this program, participants are able to:

• Discuss the key mechanisms and terminology of tumor immunology and immunotherapy
• Describe the role of immunity in cancer and approaches to tumor immunotherapy
• Implement cancer immunotherapy treatments for melanoma, lung cancer and/or genitourinary cancers into clinical practice more effectively through a sound understanding of mechanisms of action, side effects and clinical management, and efficacy
• Provide appropriate care and counsel for patients and their families
• Provide accurate and appropriate counsel as part of the treatment team

Planning Committee

Asim Amin, MD, PhD – Levine Cancer Institute Carolinas Medical Center
Joseph W. Fay, MD – Baylor University Medical Center
Hideho Okada, MD, PhD – University of California San Francisco
John D. Powderly II, MD, CPI – Carolina BioOncology Institute, PLLC
Brian I. Rini, MD – Cleveland Clinic Taussig Cancer Center
Alexander Spira, MD, PhD – Virginia Cancer Specialists
Laura S. Wood, RN, MSN, OCN – Cleveland Clinic Taussig Cancer Center
Eleni Yeatras, RPh, BCOP – Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer

In collaboration with the University of Chicago Medicine Comprehensive Cancer Center

The Advances in Cancer Immunotherapy^™ series is supported in part by independent medical educational grants from AstraZeneca, Bristol-Myers Squibb, Genentech, and Merck & Co., Inc.

Event staff will be glad to assist you with any special needs (i.e., physical, dietary, etc.). Please contact SITC prior to the live event at (414) 271-2456.

View a list of upcoming Advances in Cancer Immunotherapy^TM 2016 regional programs.